The efficacy and safety of Tipapkinogen Sovacivec therapeutic HPV vaccine in cervical intraepithelial neoplasia grades 2 and 3: Randomized controlled phase II trial with 2.5 years of follow-up  Diane M. Harper, Pekka Nieminen, Gilbert Donders, Mark H. Einstein, Francisco Garcia, Warner K. Huh, Mark H. Stoler, Katerina Glavini, Gemma Attley, Jean-Marc Limacher, Berangere Bastien, Elizabeth Calleja  Gynecologic Oncology  DOI: 10.1016/j.ygyno.2019.03.250 Copyright © 2019 The Authors Terms and Conditions

Fig. 1 Trial schematic—700 Patients Screened and subsequent enrollment in the safety population and the modified intent to treat (mITT) population. Gynecologic Oncology DOI: (10.1016/j.ygyno.2019.03.250) Copyright © 2019 The Authors Terms and Conditions

Fig. 2 Viral DNA clearance by Roche Linear Array Assay Fig. 2A. Among baseline CIN 2/3 regardless of HR HPV types through month 30, mITT. Fig. 2B. Among baseline CIN 3 regardless of HR HPV types through month 30, mITT. Fig. C. Among baseline CIN 2/3 by HR HPV type through month 30, mITT. Gynecologic Oncology DOI: (10.1016/j.ygyno.2019.03.250) Copyright © 2019 The Authors Terms and Conditions